CytomX Therapeutics, Inc. Research and Development in Process
CytomX Therapeutics, Inc. (CTMX) reported Research and Development in Process of $10.70 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2020-02-27
- CytomX Therapeutics, Inc. research and development in process for the quarter ending 2017-12-31 was $0.00.
- CytomX Therapeutics, Inc. research and development in process for fiscal 2017 was $10.70M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $10.70M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $10.70M 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |